One-step enzyme-linked immunosorbent assay (ELISA) for measurement of serum free leptin

Kimura, E; Matsumoto, Kyoichi; Samori, Tomohiro; Kato, Seiji; Kawahara, Teppei

doi:10.1016/s0009-8981(00)00203-5

Cited by 7 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reliability of these measurements has been well established. [11][12][13][14][15] Statistical analysis: Neither serum leptin nor adiponectin levels showed Gaussian distribution, and the natural logarithmic transformed (ln) values of each adipocytokine were used. Values are expressed as the mean ± SE.…”

Section: Methodsmentioning

confidence: 99%

Association of Circulating Levels of Leptin and Adiponectin With Metabolic Syndrome and Coronary Heart Disease in Patients With Various Coronary Risk Factors

et al. 2011

View full text Add to dashboard Cite

SummaryThe aim of this study was to investigate the associations of adiponectin and leptin with metabolic syndrome (MetS) and coronary heart disease (CHD) in patients with various coronary risk factors. We determined serum adiponectin, leptin, and metabolic syndrome components in 104 patients (59 men and 45 women; aged 40-86 years) with various coronary risk factors at a cardiovascular out-patient clinic. Natural logarithmic transformed (ln) leptin was lower in men and smokers, and positively correlated with body mass index (BMI) (r = 0.59, P < 0.0001), waist circumference (r = 0.60, P < 0.0001), and homeostasis model assessment of insulin resistance (HOMA-IR) levels (r = 0.24, P < 0.02). Ln adiponectin was higher in women and nonsmokers, and was correlated with age and high-density lipoprotein cholesterol (HDL-C). Patients with MetS (n = 69) had significantly higher BMI, HOMA-IR, and ln leptin and lower ln adiponectin than those without Mets (Ln leptin, 2.14 ± 0.08 versus 1.30 ± 0.11; Ln adiponectin, 2.29 ± 0.06 versus 2.54 ± 0.09). In contrast, patients with coronary heart disease (CHD: n = 40) had significantly lower serum ln adiponectin concentrations than non-CHD patients (n = 64) (1.79 ± 0.12 versus 1.91 ± 0.10) as well as lower HDL-C and a higher smoking percentage. Consistent results were obtained by multivariate analyses. In conclusion, this study disclosed factors associated with the increase in serum leptin and adiponectin. Serum levels of leptin may be associated positively with MetS, whereas adiponectin levels are associated negatively with MetS and CHD, even in patients with various coronary risk factors. (Int Heart J 2011; 52: 17-22)

show abstract

Section: Methodsmentioning

confidence: 99%

Association of Circulating Levels of Leptin and Adiponectin With Metabolic Syndrome and Coronary Heart Disease in Patients With Various Coronary Risk Factors

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Further, another type of adipokine is directly involved with body fat, and it is the main factor that is associated with obesity-related diseases. Several studies have reported that plasma leptin levels are higher in overweight and obese individuals than normal-weight individuals [ 12 13 ]. Many studies have shown that decreased adiponectin levels and elevated leptin levels are associated with obesity-linked cancers [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer

Jin

Kim

et al. 2016

Obstet Gynecol Sci

View full text Add to dashboard Cite

ObjectiveDecreased adiponectin and increased leptin plasma concentrations are believed to be associated with the occurrence and progression of cancers such as endometrial cancer and breast cancer. The aim of this study was to explore the association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer.MethodsFor patients with ovarian cancer and the control group, adiponectin and leptin levels were measured; anthropometric data were obtained during a chart review. Statistical comparisons between groups were analyzed using the Student's t-test; correlations were confirmed using the Pearson correlation.ResultsThe mean adiponectin and leptin concentrations in patients with ovarian cancer were lower than those of the control group (8.25 vs. 11.44 µg/mL, respectively; P=0.026) (7.09 vs. 15.4 ng/mL, respectively; P=0.001). However, there was no significant difference in adiponectin and leptin levels between early-stage (I/II) and advanced-stage (III/IV) disease (P=0.078).ConclusionCompared with other gynecological cancers, the level of adiponectin and leptin were decreased in ovarian cancer that may have some diagnostic value; additional study to elucidate the function of these two hormones in the development of ovarian carcinogenesis is necessitated.

show abstract

“…Serum leptin level was estimated by the method of sandwich ELISA assay using leptin ELISA kits supplied by Cell Biolabs, Inc., USA (Kimura et al, 2000).…”

Section: Leptin Assaymentioning

confidence: 99%

Amelioration of the Abnormalities Associated with Metabolic Syndrome by L-Norvaline in Hyperlipidemic Diabetic Rats

Dobhal¹,

Baliyan²,

Singh³

et al. 2021

European Pharmaceutical Journal

View full text Add to dashboard Cite

The present study was designed to assess the treatment effect of arginase inhibitor, L-Norvaline in abnormalities associated with high fat diet (HFD) and fructose-induced metabolic syndrome. The HFD and fructose was fed to the rats for a period of 45 days. Animals having body weight of 350 g and fasting blood sugar level of more than 250 mg/dl were considered as hyperlipidemic diabetic rats (HDR) and selected for the study. The HDR were divided into three groups having six animals each. The HDR received L–Norvaline (10 mg/kg/day, i.p.) and standard drug, gemfibrozil (60 mg/kg/day, p.o.), for a period of 30 days. Various hormonal, biochemical and tissue parameters were evaluated at the end of the study. Both treatments significantly decreased body weight, BMI, fasting blood sugar and insulin level and improved insulin resistance in HDR as compared to the toxicant control group. A significant improvement was observed in the lipid profile, levels of nitrate, leptin, C-reactive protein and adiponectin in HDR. L-Norvaline also caused slight decrease in the malondialdehyde level, though, no prominent effect was observed on the level of superoxide dismutase and reduced glutathione in the pancreas of HDR, as compared to the toxicant control group. L-Norvaline treatment also improved the histo-architecture of pancreatic cells. Results of the present study concludes that L-Norvaline caused significant alleviation of the abnormalities of MetS indicating that it can be used as potential treatment strategy for managing the symptoms of metabolic syndrome.

show abstract

One-step enzyme-linked immunosorbent assay (ELISA) for measurement of serum free leptin

Cited by 7 publications

References 33 publications

Association of Circulating Levels of Leptin and Adiponectin With Metabolic Syndrome and Coronary Heart Disease in Patients With Various Coronary Risk Factors

Association of Circulating Levels of Leptin and Adiponectin With Metabolic Syndrome and Coronary Heart Disease in Patients With Various Coronary Risk Factors

Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer

Amelioration of the Abnormalities Associated with Metabolic Syndrome by L-Norvaline in Hyperlipidemic Diabetic Rats

Contact Info

Product

Resources

About